WO1995012392A1 - Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules - Google Patents

Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules Download PDF

Info

Publication number
WO1995012392A1
WO1995012392A1 PCT/US1994/012515 US9412515W WO9512392A1 WO 1995012392 A1 WO1995012392 A1 WO 1995012392A1 US 9412515 W US9412515 W US 9412515W WO 9512392 A1 WO9512392 A1 WO 9512392A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
pairs
matter according
particles
core particle
Prior art date
Application number
PCT/US1994/012515
Other languages
English (en)
Inventor
Nir Kossovsky
Edward Sponsler
Andrew Gelman
H. James Hnatyszyn
Samir Rajguru
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/145,870 external-priority patent/US5460830A/en
Priority claimed from US08/146,536 external-priority patent/US5462751A/en
Priority claimed from US08/147,751 external-priority patent/US5460831A/en
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to JP7513349A priority Critical patent/JPH09504790A/ja
Priority to EP95901094A priority patent/EP0726767A4/fr
Publication of WO1995012392A1 publication Critical patent/WO1995012392A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

L'invention concerne une composition à activité biologique qui comprend des particules noyaux ou des surfaces qui sont recouvertes d'une couche favorisant la fixation de paires à réaction biochimique (BRP) sans les dénaturer. Les BRP susceptibles d'être fixées comprennent les paires ligand-récepteur, les paires enzyme-substrat, les paires médicament-récepteur, les paires catalyseur-réactant, les paires toxine-ligand, les paires absorbant-absorbat et les paires adsorbant-adsorbat. L'invention concerne en outre des compositions à activité biologique composées de particules noyaux biodégradables recouvertes d'une couche destinée à favoriser la fixation d'agents à activité biologique sans les dénaturer. Ces compositions peuvent également contenir une membrane extérieure de ciblage qui confère un ciblage sélectif aux récepteurs spécifiques. L'invention concerne par ailleurs des compositions à activité biologique qui s'utilisent en thérapie génique, ainsi que d'autres procédés de transfection. Ces compositions comprennent des particules noyaux nanocristallines qui sont recouvertes d'une couche destinée à favoriser la fixation d'agents de transfection (segments d'ADN/d'ARN et fragments anti-sens) sans les dénaturer. Ces compositions peuvent en outre contenir une membrane extérieure de ciblage qui confère un ciblage sélectif des agents de transfection aux récepteurs de cellules spécifiques.
PCT/US1994/012515 1993-11-01 1994-10-31 Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules WO1995012392A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP7513349A JPH09504790A (ja) 1993-11-01 1994-10-31 化学的触媒作用および細胞受容体活性化のための生化学的活性物質
EP95901094A EP0726767A4 (fr) 1993-11-01 1994-10-31 Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/145,870 US5460830A (en) 1990-06-22 1993-11-01 Biochemically active agents for chemical catalysis and cell receptor activation
US08/145,870 1993-11-01
US08/146,536 1993-11-01
US08/146,536 US5462751A (en) 1990-06-22 1993-11-01 Biological and pharmaceutical agents having a nanomeric biodegradable core
US08/147,751 US5460831A (en) 1990-06-22 1993-11-04 Targeted transfection nanoparticles
US08/147,751 1993-11-04

Publications (1)

Publication Number Publication Date
WO1995012392A1 true WO1995012392A1 (fr) 1995-05-11

Family

ID=27386330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012515 WO1995012392A1 (fr) 1993-11-01 1994-10-31 Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules

Country Status (4)

Country Link
EP (1) EP0726767A4 (fr)
JP (1) JPH09504790A (fr)
CA (1) CA2174244A1 (fr)
WO (1) WO1995012392A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017948A1 (fr) * 1994-12-09 1996-06-13 The Regents Of The University Of Michigan Procede, compositions et appareil pour la transfection cellulaire
WO1997023241A1 (fr) * 1995-12-21 1997-07-03 Quest International B.V. Compositions de particules
US5672494A (en) * 1993-10-08 1997-09-30 The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
EP0833667A1 (fr) * 1995-06-07 1998-04-08 The Regents Of The University Of California Stabilisation de complexes de polynucleotides
EP0836645A1 (fr) * 1995-06-09 1998-04-22 The Regents Of The University Of California Formulations en poudre seche a base de complexes polynucleotidiques
WO1999030741A2 (fr) * 1997-12-12 1999-06-24 Max-Delbrück-Centrum für Molekulare Medizin Agent pour la therapie genique de tumeurs, maladies neurodegeneratives, cardiovasculaires et auto-immunes
EP1063286A1 (fr) * 1998-02-09 2000-12-27 Toyo Kohan Co., Ltd Substrats d'immobilisation et d'amplification de l'adn, cristaux de blocage d'adn avec de l'adn bloque sur les substrats, et procede d'amplification de l'adn
WO2002032568A1 (fr) * 2000-10-18 2002-04-25 Toyo Kohan Co., Ltd. Support particulaire pour effectuer une separation/purification ou une extraction et procede de production dudit support
US7323297B1 (en) 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
US10792649B2 (en) 2015-07-15 2020-10-06 Zymtronix, Llc Automated bionanocatalyst production
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
US10993436B2 (en) 2016-08-13 2021-05-04 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041812A1 (en) * 2004-11-01 2009-02-12 Bell Steve J D Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
ES2557183B1 (es) * 2014-07-21 2016-11-03 Consejo Superior De Investigaciones Científicas (Csic) Procedimiento de obtención de nanopartículas de fosfato de calcio amorfo recubiertas de citrato y dopadas con flúor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
CA1252950A (fr) * 1984-11-23 1989-04-18 Heinz Gries Particules magnetiques pour fins diagnostiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5306508A (en) * 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
CA1252950A (fr) * 1984-11-23 1989-04-18 Heinz Gries Particules magnetiques pour fins diagnostiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0726767A4 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323297B1 (en) 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
US5672494A (en) * 1993-10-08 1997-09-30 The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US5866400A (en) * 1993-10-08 1999-02-02 The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US5654185A (en) * 1994-12-09 1997-08-05 The Regents Of The University Of Michigan Methods, compositions and apparatus for cell transfection
US5804431A (en) * 1994-12-09 1998-09-08 The Regents Of The University Of Michigan Method, compositions and apparatus for cell transfection
US5811274A (en) * 1994-12-09 1998-09-22 The Regents Of The University Of Michigan Methods, compositions and apparatus for cell transfection
WO1996017948A1 (fr) * 1994-12-09 1996-06-13 The Regents Of The University Of Michigan Procede, compositions et appareil pour la transfection cellulaire
EP0833667A4 (fr) * 1995-06-07 2001-11-21 Univ California Stabilisation de complexes de polynucleotides
EP0833667A1 (fr) * 1995-06-07 1998-04-08 The Regents Of The University Of California Stabilisation de complexes de polynucleotides
EP1491217A1 (fr) * 1995-06-07 2004-12-29 The Regents Of The University Of California Stabilisation de complexes de polynucléotides
EP0836645A1 (fr) * 1995-06-09 1998-04-22 The Regents Of The University Of California Formulations en poudre seche a base de complexes polynucleotidiques
EP0836645A4 (fr) * 1995-06-09 2001-11-21 Univ California Formulations en poudre seche a base de complexes polynucleotidiques
WO1997023241A1 (fr) * 1995-12-21 1997-07-03 Quest International B.V. Compositions de particules
WO1999030741A3 (fr) * 1997-12-12 1999-08-19 Max Delbrueck Centrum Agent pour la therapie genique de tumeurs, maladies neurodegeneratives, cardiovasculaires et auto-immunes
WO1999030741A2 (fr) * 1997-12-12 1999-06-24 Max-Delbrück-Centrum für Molekulare Medizin Agent pour la therapie genique de tumeurs, maladies neurodegeneratives, cardiovasculaires et auto-immunes
EP1063286A4 (fr) * 1998-02-09 2004-03-24 Toyo Kohan Co Ltd Substrats d'immobilisation et d'amplification de l'adn, cristaux de blocage d'adn avec de l'adn bloque sur les substrats, et procede d'amplification de l'adn
EP1063286A1 (fr) * 1998-02-09 2000-12-27 Toyo Kohan Co., Ltd Substrats d'immobilisation et d'amplification de l'adn, cristaux de blocage d'adn avec de l'adn bloque sur les substrats, et procede d'amplification de l'adn
WO2002032568A1 (fr) * 2000-10-18 2002-04-25 Toyo Kohan Co., Ltd. Support particulaire pour effectuer une separation/purification ou une extraction et procede de production dudit support
CN1322914C (zh) * 2000-10-18 2007-06-27 东洋钢钣株式会社 分离/纯化或提取用粒状载体及其生产方法
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
US11517014B2 (en) 2015-05-18 2022-12-06 Zymtronix, Inc. Magnetically immobilized microbiocidal enzymes
US10792649B2 (en) 2015-07-15 2020-10-06 Zymtronix, Llc Automated bionanocatalyst production
US10993436B2 (en) 2016-08-13 2021-05-04 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals

Also Published As

Publication number Publication date
CA2174244A1 (fr) 1995-05-11
EP0726767A1 (fr) 1996-08-21
JPH09504790A (ja) 1997-05-13
EP0726767A4 (fr) 1997-08-20

Similar Documents

Publication Publication Date Title
US5462751A (en) Biological and pharmaceutical agents having a nanomeric biodegradable core
US5460830A (en) Biochemically active agents for chemical catalysis and cell receptor activation
US5334394A (en) Human immunodeficiency virus decoy
US5178882A (en) Viral decoy vaccine
US5460831A (en) Targeted transfection nanoparticles
US5219577A (en) Biologically active composition having a nanocrystalline core
WO1995012392A1 (fr) Agents a activite biochimique pour catalyse chimique et activation de recepteur de cellules
US5464634A (en) Red blood cell surrogate
Pierigè et al. Cell-based drug delivery
JP4142095B2 (ja) 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
US7855180B2 (en) Structure and method for releasing substance therefrom
Kossovsky et al. Surface-modified nanocrystalline ceramics for drug delivery applications
Jain et al. Aquasomes: A novel drug carrier
IL144084A (en) Therapeutic calcium phosphate particles and methods of manufacture and use
US5306508A (en) Red blood cell surrogate
CN114452266B (zh) 一种基于重组核糖体蛋白的核酸药物递送系统及其制备方法和应用
JP4965022B2 (ja) 安定化されたタンパク質結晶、それを含む処方物、およびそれを作製する方法
Grimaldi et al. Engineered liposomes and virosomes for delivery of macromolecules
CN110540589B (zh) 一种多肽、多肽修饰的脂质载体及应用
US20220088079A1 (en) Metabolite encapsulating nanoparticles to enhance cellular cancer immunotherapy
CN115429774A (zh) 一种仿生膜包裹尿酸酶纳米粒及其制备方法
Kossovsky et al. Self Assembling Nanostructured Delivery Vehicles for Biochemically Reactive Pairs
Öner et al. Bioactive molecules and biodelivery systems

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2174244

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995901094

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995901094

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995901094

Country of ref document: EP